Medibank Private Ltd (ASX: MPL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Medibank Private Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $9.53 billion
P/E Ratio 21.74
Dividend Yield 3.65%
Shares Outstanding 2.75 billion
Earnings per share 0.160
Dividend per share 0.14
Year To Date Return 19.83%
Earnings Yield 4.60%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Medibank Private Ltd (ASX: MPL)
Latest News

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
08 Sep 2021 $0.0690 100.00% Final 30 Sep 2021
03 Mar 2021 $0.0580 100.00% Interim 25 Mar 2021
02 Sep 2020 $0.0630 100.00% Final 24 Sep 2020
03 Mar 2020 $0.0570 100.00% Interim 26 Mar 2020
04 Sep 2019 $0.0250 100.00% 26 Sep 2019
04 Sep 2019 $0.0740 100.00% Final 26 Sep 2019
05 Mar 2019 $0.0570 100.00% Interim 28 Mar 2019
05 Sep 2018 $0.0720 100.00% Final 27 Sep 2018
06 Mar 2018 $0.0550 100.00% Interim 28 Mar 2018
06 Sep 2017 $0.0675 100.00% Final 28 Sep 2017
07 Mar 2017 $0.0525 100.00% Interim 29 Mar 2017
06 Sep 2016 $0.0600 100.00% Final 28 Sep 2016
04 Mar 2016 $0.0500 100.00% Interim 29 Mar 2016
03 Sep 2015 $0.0530 100.00% 28 Sep 2015

MPL ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Medibank Private Ltd

Medibank Private Ltd (ASX: MPL) is an integrated healthcare company providing private health insurance and health solutions to 3.7 million Australians. Medibank’s core business is the underwriting and distribution of private health insurance policies – as well as travel, life and pet insurances – through its two brands, Medibank and AHM.

Medibank offers hospital cover and extras cover to customers in Australia as well as health insurance to overseas visitors and students. It also provides integrated healthcare services to policyholders, government, corporate and other customers. These include mental health support, preventative and better integrated primary care and after-hours health support.

Established as a not-for-profit private health insurer by the Australian government in 1976, Medibank was sold and listed on ASX in 2014. The Medibank share price peaked at $3.67 in July 2019.

MPL Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
26 Oct 2021 $3.46 $-0.01 -0.29% 3,682,762 $3.48 $3.49 $3.43
25 Oct 2021 $3.47 $-0.01 -0.29% 4,233,653 $3.47 $3.49 $3.45
22 Oct 2021 $3.48 $0.01 0.29% 5,379,226 $3.45 $3.50 $3.45
21 Oct 2021 $3.47 $0.04 1.17% 7,279,980 $3.45 $3.49 $3.42
20 Oct 2021 $3.43 $-0.04 -1.15% 9,734,098 $3.50 $3.50 $3.42
19 Oct 2021 $3.47 $0.00 0.00% 8,447,883 $3.48 $3.49 $3.46
18 Oct 2021 $3.47 $-0.03 -0.86% 3,836,080 $3.48 $3.50 $3.46
15 Oct 2021 $3.50 $0.00 0.00% 4,066,507 $3.50 $3.52 $3.45
14 Oct 2021 $3.50 $-0.02 -0.57% 1,926,307 $3.54 $3.54 $3.49
13 Oct 2021 $3.52 $0.02 0.57% 4,233,830 $3.51 $3.53 $3.49
12 Oct 2021 $3.50 $-0.02 -0.57% 6,824,372 $3.51 $3.53 $3.47
11 Oct 2021 $3.52 $-0.05 -1.40% 6,494,867 $3.55 $3.57 $3.51
08 Oct 2021 $3.57 $0.03 0.85% 4,569,829 $3.58 $3.59 $3.53
07 Oct 2021 $3.54 $-0.02 -0.56% 6,970,628 $3.53 $3.57 $3.52
06 Oct 2021 $3.56 $0.04 1.14% 5,791,746 $3.55 $3.58 $3.53
05 Oct 2021 $3.52 $-0.02 -0.56% 4,090,530 $3.51 $3.55 $3.50
04 Oct 2021 $3.54 $0.01 0.28% 3,985,281 $3.50 $3.57 $3.50
01 Oct 2021 $3.53 $-0.06 -1.67% 6,300,922 $3.50 $3.56 $3.50
30 Sep 2021 $3.59 $0.07 1.99% 9,010,608 $3.55 $3.61 $3.55
29 Sep 2021 $3.52 $-0.01 -0.28% 6,137,137 $3.50 $3.54 $3.48
28 Sep 2021 $3.53 $-0.06 -1.67% 2,607,243 $3.55 $3.57 $3.53

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
27 Aug 2021 David Koczkar Exercise 65 $229,608
Conversion of securities. 525,187 - Performance Rights
27 Aug 2021 David Koczkar Buy 65 $229,608
Conversion of securities.
27 Aug 2021 David Koczkar Expiry 138 $487,913
As advised by the company. 386,968 - Performance Rights
138,219 lapsed Performance Rights
26 Nov 2020 Craig Drummond Issued 761 $2,217,187
Issue of securities. 2,217,668 - Performance Rights.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Michael (Mike) John Wilkins Non-Executive DirectorNon-Executive Chairman May 2017
Mr Wilkins has more than 30 years of experience in financial services, predominantly in Australia and Asia. He served as Managing Director and Chief Executive Officer at Insurance Australia Group (November 2007 to November 2015), Managing Director and Chief Executive Officer at Promina Group Limited and Managing Director at Tyndall Australia Limited. He also served as Acting Chief Executive Officer (April 2018 to December 2018), Executive Chairman (April 2018 to June 2018) and a director (September 2016 to February 2020) of AMP Limited. He was previously a director of Maple-Brown Abbott Limited, Alinta Limited, The Geneva Association and the Australian Business and Community Network. He is a member of the Investment, and Capital and the People Committee.
Mrs Linda Bardo Nicholls Non-Executive Director Mar 2014
Mrs Nicholls has more than 30 years of experience as a senior executive and director in banking, insurance and funds management in Australia, New Zealand and the United States. She is currently Chairman of Japara Healthcare Limited (since March 2014) and a director of Inghams Group Limited (since November 2016). Linda is also Chairman of the Board of Melbourne Health and a member of the Museums Board of Victoria. Linda's previous directorships include Fairfax Media Limited (February 2010 to December 2018), Pacific Brands Limited (October 2013 to July 2016), Sigma Pharmaceuticals Limited (December 2005 to December 2015) and Healthscope Limited, as Chairman (October 2008 to October 2010) and a director (January 2000 to October 2010). She is Chairman of the People committee.
Ms Christine Elizabeth O'Reilly Non-Executive Director Mar 2014
Ms O'Reilly has more than 30 years of financial and infrastructure experience both in Australia and internationally in various roles including as Co-head of Unlisted Infrastructure at Colonial First State Global Asset Management and Chief Executive and Managing Director of GasNet Australia Group. Christine's early career includes eight years in investment banking and audit experience with Price Waterhouse, where she qualified as a chartered accountant. Her previous directorships include CSL Limited (February 2011 to October 2020) and the Transurban Group (April 2012 to October 2020). She is a member of the Risk committee.
Mr Peter Hodgett Non-Executive Director Jun 2013
Mr Hodgett held a number of other non-executive directorships from 2008 and is currently a director of the Leukaemia Foundation of Australia. Previously, Peter worked for AMP for more than 20 years in a wide variety of business and functional roles, including Chief Actuary during its demutualisation, General Manager of Human Resources and Strategy, and as Global Director of Finance and Operations for Henderson Global Investors in the United Kingdom. He is Chairman of the Investment and Capital Committee.
Mr David Fagan Non-Executive Director Mar 2014
Mr Fagan held a variety of positions at Clayton Utz culminating in the role of Chief Executive Partner for nine years. In this role, David had responsibility and accountability for transformation, strategy, finance, stakeholder engagement, and governance, including risk management. During David's tenure as Chief Executive Partner, Clayton Utz entrenched itself as a first class top tier commercial law firm. David also chaired the Medibank Privatisation Committee which operated during 2014 in preparation for the privatisation process. David is a former director and Chair of the Audit Committee of The Global Foundation, a former director of Grocon Funds Management Group, the Hilco Group and UBS Grocon Real Estate Investment Management Australia Pty Limited and a former member of the advisory board of Chase Corporate Advisory. David is currently a director of PayGroup Limited (since November 2017). He is Chair of BDO Group Holdings Limited and a member of the ASIC Corporate Governance Consultative Panel. He is Chairman of the Risk Management Committee and a member of the Investment and Capital Committee.
Ms Anna Bligh Non-Executive Director Dec 2014
Ms Bligh has experience in the fields of healthcare, finance, infrastructure and project management. She has held several roles in the Queensland Government, including Premier, Treasurer, Minister for Finance, Minister for State Development, Minister for Trade and Innovation and Minister for Education. She was also a member of the Queensland Cabinet Budget Review Committee for 11 years. Anna was a director of Bangarra Dance Theatre Australia (2012-2020) and is currently a non-executive director of Australian Plays Transform. She is a member of the Investment and Capital and the People Committee.
Mr David Koczkar Chief Executive OfficerManaging Director May 2021
Mr Koczkar has more than 25 years of strategy, customer and commercial experience, including previous work in the strategy consulting and financial services industries. Prior to joining Medibank, David was the Group Chief Commercial Officer at Jetstar where he was responsible for the airline group's network management, sales and marketing, customer channels and commercial operations, including as a director of Jetstar Pacific (Vietnam), Jetstar Hong Kong and NewStar (Singapore) JV businesses.
Dr Tracey Batten Non-Executive Director Aug 2017
Dr Batten has experience in the health services sector, with commercial, business and change skills. Tracey is currently a director of EBOS Group Limited (since July 2021), the National Institute of Water and Atmospheric Research in New Zealand and the New Zealand Accident Compensation Corporation, and a former director of Abano Healthcare Group. Tracey was previously the Chief Executive of the Imperial College Healthcare NHS Trust in the United Kingdom. In that role, Tracey focused on change leadership, in particular improving organisational culture and strengthening patient safety and experience. Tracey also oversaw the implementation of a range of digital initiatives as Chief Executive. Tracey is a former Chief Executive of St Vincent's Health Australia, which runs a group of public hospitals, private hospitals and aged care facilities. She is a member of the Risk Management and the People committee.
Mr Gerard Dalbosco Non-Executive Director May 2021
Mr Dalbosco held a number of senior roles as a Partner of EY until September 2020. His most recent role was Melbourne Managing Partner where he led a large team responsible for EYs go-to-market and client service strategies. Prior to this, Gerard held other roles at EY including Asia Pacific Managing Partner -Markets and Co-Deputy CEO where he led EYs client-serving activities across the Asia Pacific market. He was also Oceania Managing Partner and CEO, and Oceania Managing Partner of Transaction Advisory Services where he was responsible for EYs Transaction Advisory Services business across Oceania. Gerard is currently Chair of Melbourne Archdiocese Catholic Schools and Co-Deputy Chair and Chair of the Finance Committee of the Committee for Melbourne. He has previously held roles as a director and Chair of the Finance & Audit Committee of Mercy Health & Aged Care, director and member of the Finance Committee of Berry Street Victoria, and Chair of the National Gallery of Victoria's Business Council. He is a member of the Risk Management Committee.
Ms Mei Ramsay Group General CounselCompany Secretary Mar 2011
-
Mark Rogers Group Executive - Chief Financial Officer & Group Strategy
-
Dr Andrew Wilson Group Executive - CEO Health Services
-
Rob Deeming Group Executive - Customer & Brands
-
Milosh Milisavljevic Group Executive - Customer Portfolios
-
Kylie Bishop Group Executive - People & Culture
-
John Goodall Group Executive - Technology & Operations
-
Mei Ramsay Group General CounselCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 844,196,960 30.65%
J P Morgan Nominees Australia Pty Limited 515,398,135 18.71%
Citicorp Nominees Pty Limited 269,831,924 9.80%
National Nominees Limited 144,394,624 5.24%
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 64,160,779 2.33%
BNP Paribas Noms Pty Ltd <Drp> 52,703,501 1.91%
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/ 23,213,664 0.84%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 20,179,643 0.73%
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 13,969,892 0.51%
Netwealth Investments Limited <Wrap Services A/C> 6,541,236 0.24%
The Senior Master Of The Supreme Court <Common Fund No 3 A/C> 6,500,000 0.24%
Navigator Australia Ltd <Sma Antares Inv Dv Build A/C> 6,150,413 0.22%
Australian Executor Trustees Limited <IPS Super A/c> 6,054,833 0.22%
BNP Paribas Nominees Pty Ltd Acf Clearstream 5,412,538 0.20%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 5,267,074 0.19%
Netwealth Investments Limited <Super Services A/C> 3,609,344 0.13%
BNP Paribas Noms Pty Ltd <Arbitage Snc Drp> 3,433,369 0.12%
National Nominees Limited <Db A/C> 3,413,056 0.12%
Neweconomy Com Au Nominees Pty Limited <900 Account> 3,322,276 0.12%
AMP Life Limited 3,013,952 0.11%

Profile

since

Note